Compare Recursion Pharmaceuticals Inc (RXRX) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Banco Santander SA — how do they compare? Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B), while Banco Santander SA trades at $13.74 (market cap $191.46B). The key difference: Banco Santander SA is far larger — about 125.1× Recursion Pharmaceuticals Inc's market cap, and Banco Santander SA pays a 2.09% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SAN | |
|---|---|---|
Market Cap | $1.53B | $191.46B |
Sector | Health | Financials |
52-Week High | $6.79 | $14.37 |
52-Week Low | $2.84 | $8.40 |
Enterprise Value | $946.50M | — |
Dividend Yield | — | 2.09% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
